# OnCo record arrivent (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/arrivent/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "arrivent" ;
  schema:name "ArriVent BioPharma"@en ;
  schema:alternateName "ArriVent BioPharma, Inc."@en, "ArriVent"@en ;
  schema:description "ArriVent is a Pennsylvania company developing furmonertinib, an EGFR inhibitor approved in China, for EGFR exon 20 insertion and other uncommon EGFR-mutant lung cancers in global trials."@en ;
  schema:url <https://onco.cc/companies/arrivent/>, <https://www.arrivent.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.arrivent.com>, <https://clinicaltrials.gov/search?lead=ArriVent%20BioPharma> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/furmonertinib/> ;
  onco:trials <https://onco.cc/trials/nct05607550/>, <https://onco.cc/trials/nct07185997/> .